CATALOGO DEI PRODOTTI DELLA RICERCA

Bria, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.459
NA - Nord America 8.536
AS - Asia 6.958
SA - Sud America 918
AF - Africa 115
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 11
Totale 26.012
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.410
RU - Federazione Russa 3.697
SG - Singapore 2.851
CN - Cina 2.645
GB - Regno Unito 2.089
BR - Brasile 721
HK - Hong Kong 604
DE - Germania 593
FR - Francia 587
IT - Italia 583
FI - Finlandia 532
SE - Svezia 489
IE - Irlanda 488
VN - Vietnam 402
NL - Olanda 98
UA - Ucraina 95
KR - Corea 78
IN - India 77
AR - Argentina 73
CA - Canada 57
JP - Giappone 46
PL - Polonia 45
ID - Indonesia 41
EC - Ecuador 40
MX - Messico 40
ZA - Sudafrica 37
TR - Turchia 35
BE - Belgio 32
BD - Bangladesh 31
IQ - Iraq 26
ES - Italia 24
CH - Svizzera 22
AT - Austria 20
MA - Marocco 17
PY - Paraguay 17
VE - Venezuela 17
CO - Colombia 16
IR - Iran 15
CL - Cile 14
EU - Europa 14
PK - Pakistan 13
LT - Lituania 11
TG - Togo 11
UZ - Uzbekistan 11
AZ - Azerbaigian 10
NP - Nepal 10
SA - Arabia Saudita 10
EG - Egitto 9
KE - Kenya 9
PE - Perù 9
BJ - Benin 8
CZ - Repubblica Ceca 8
PH - Filippine 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
LV - Lettonia 7
BO - Bolivia 6
CR - Costa Rica 6
OM - Oman 6
HN - Honduras 5
TN - Tunisia 5
AL - Albania 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
GR - Grecia 4
MK - Macedonia 4
PT - Portogallo 4
UY - Uruguay 4
AM - Armenia 3
BG - Bulgaria 3
JM - Giamaica 3
LK - Sri Lanka 3
MY - Malesia 3
NI - Nicaragua 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
RS - Serbia 3
BH - Bahrain 2
CI - Costa d'Avorio 2
CM - Camerun 2
EE - Estonia 2
GA - Gabon 2
JO - Giordania 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MW - Malawi 2
PS - Palestinian Territory 2
RO - Romania 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
Totale 25.995
Salva come PNG Salva come JPEG
Città #
Southend 1.886
Singapore 1.315
Moscow 1.143
Chandler 1.084
Woodbridge 955
Dallas 828
Ann Arbor 620
Hong Kong 597
Ashburn 523
Dublin 484
Beijing 468
Jacksonville 442
Houston 411
The Dalles 264
Jinan 247
Lawrence 236
Princeton 236
Wilmington 191
Nanjing 187
Munich 186
New York 182
Shenyang 157
Los Angeles 156
Ho Chi Minh City 149
Helsinki 123
Hebei 118
Redondo Beach 106
Tianjin 105
Verona 101
Buffalo 91
Hanoi 85
Changsha 78
Ningbo 77
Haikou 70
Milan 68
São Paulo 63
Zhengzhou 60
Nanchang 59
Guangzhou 58
Hangzhou 57
Santa Clara 57
Sindelfingen 54
Columbus 53
Jiaxing 49
Taizhou 47
Seoul 44
Tokyo 40
Turku 39
Taiyuan 38
London 37
Seattle 35
Council Bluffs 33
Brussels 32
Fuzhou 30
Rio de Janeiro 27
San Francisco 27
Warsaw 27
Lanzhou 26
Norwalk 26
Boardman 24
Denver 24
Falls Church 24
Redwood City 24
Rome 24
Brooklyn 23
Dearborn 23
Johannesburg 23
Montreal 23
Chicago 22
Lancaster 22
Frankfurt am Main 21
Stockholm 20
Chennai 19
Mexico City 19
Amsterdam 18
Orem 18
Nuremberg 17
Quito 17
Atlanta 16
Hải Dương 16
Phoenix 16
Belo Horizonte 15
Bologna 15
Boston 15
Jakarta 15
Meda 15
Brasília 13
Fairfield 13
Haiphong 13
Kent 13
Mumbai 13
Poplar 13
Redmond 13
Augusta 12
Biên Hòa 12
Curitiba 12
Da Nang 12
Maceió 12
Porto Alegre 12
Zurich 12
Totale 15.690
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 274
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 261
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 219
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 217
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 213
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 213
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 210
Le linee guida AIOM, ASCO e MASCC-ESMO sull'emesi da chemioterapia e radioterapia: considerazioni e approfondimenti. 199
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 193
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 189
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 187
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 184
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 183
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 182
Adenocarcinoma of the paraurethral glands: a case report 181
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis 177
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 175
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 174
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 173
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 173
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 172
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 170
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 170
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 167
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 167
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 167
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 166
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 165
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 164
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 164
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 163
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 162
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 161
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 160
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 160
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 159
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 158
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 156
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 155
The development of PARP as a successful target for cancer therapy 153
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 153
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 152
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients 148
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 148
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 145
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 143
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 141
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 141
2-weekly docetaxel: issues for clinical practice. 139
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 139
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 139
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 139
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 139
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 139
Do immune checkpoint inhibitors need new studies methodology? 137
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 136
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 136
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 134
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 134
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers 133
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 130
Acute emesis: Moderately emetogenic chemotherapy. 129
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 129
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 127
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 127
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 125
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 124
Clinical meta-analyses of targeted therapies in adenocarcinoma. 123
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 121
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 120
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 119
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 118
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 117
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 117
Adjuvant chemotherapy for bladder cancer: the chance for meta-aalyses comparison 116
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 116
Clinical meta-analyses of targeted therapies in adenocarcinoma. 115
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 115
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 115
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 114
Physical activity and exercise in lung cancer care: will promises be fulfilled? 112
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 112
Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era 111
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 111
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 111
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 111
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 109
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 108
Chemotherapy in metastatic renal cell carcinoma today? A systematic review. 107
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 107
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 107
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 106
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 105
Skin Testing and Hypersensitivity Reactions to Oxaliplatin 105
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 103
Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges 103
Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab 102
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 101
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 101
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 100
Totale 14.600
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.423
article - articoli 90.015
book - libri 478
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.930
Totale 190.846
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021382 0 0 0 0 0 136 22 14 15 19 153 23
2021/20221.660 104 543 11 157 43 30 27 99 67 41 136 402
2022/20233.118 270 268 318 585 272 753 32 191 288 19 88 34
2023/20241.541 77 112 118 155 220 225 41 191 32 70 229 71
2024/20254.445 234 266 173 799 134 157 160 215 751 326 329 901
2025/20268.386 961 701 925 1.991 3.120 688 0 0 0 0 0 0
Totale 26.255